Table 1. New drugs that have reached clinical development for treating chronic hepatitis C (/r means boosted by ritonavir).
| Drug | Manufacturer | Phase |
|---|---|---|
| NS3-4A protease inhibitors | ||
| Telaprevir | Vertex & Janssen | Approved |
| Boceprevir | Merck | Approved |
| TMC435 | Janssen | III |
| BI201335 | Boehringer-Ingelheim | III |
| Danoprevir/r | Roche/Genentech | II |
| Vaniprevir | Merck | II |
| Narlaprevir/r | Merck | II |
| Asunaprevir | Bristol-Myers Squibb | II |
| GS-9256 | Gilead | II |
| GS-9451 | Gilead | II |
| ABT-450/r | Abbott | II |
| ACH-1625 | Achillion | II |
| ACH-2684 | Achillion | Ib |
| MK-5172 | Merck | II |
| Nucleoside/nucleotide analogue inhibitors of HCV RNA-dependent RNA polymerase | ||
| PSI-7977 | Pharmasset/Gilead | III |
| Mericitabine | Roche/Genentech | II |
| IDX184 | Idenix | II |
| PSI-938 | Pharmasset/Gilead | II |
| INX-189 | Inhibitex | Ib |
| Non-nucleoside inhibitors of HCV RNA-dependent RNA polymerase | ||
| Tegobuvir | Gilead | II |
| Filibuvir | Pfizer | II |
| Setrobuvir | Roche/Genentech | II |
| BI207127 | Boehringer-Ingelheim | II |
| ABT-333 | Abbott | II |
| VX-222 | Vertex | II |
| TMC-647055 | Janssen | Ib |
| NS5A inhibitors | ||
| Daclatasvir | Bristol-Myers Squibb | II |
| PPI-461 | Presidio | Ib |
| GS-5885 | Gilead | Ib |
| GSK2336805 | GlaxoSmithKline | Ib |
| Cyclophilin inhibitors | ||
| Alisporivir | Novartis | III |
| SCY-465 | Scynexis | II |